FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
NYSE Content Update: SEC Chair Paul Atkins to Ring Opening Bell at NYSE
Revolut Aims for $150 Billion Valuation Ahead of IPO
T-Mobile US Enhances Partnership with Rogers Communications
Delta Air Lines Shares Surge 84% Over Past Year
CenterWell Launches Fulfillment Index to Define Aging Well
Mastercard Integrates AI Payment Solutions to Enhance Digital Commerce Trust
Shell Negotiates Sale of South African Fuel Retail Business to ADNOC
Kuwait Announces Force Majeure on Oil Shipments Amid Hormuz Disruptions
USA Rare Earth to Buy Brazilian Miner in $2.8 Billion Deal
Affiliates of Blue Owl to buy healthcare REIT Sila Realty Trust for $2.4 Billion
Canada’s annual CPI rises to 2.4% as Iran war spikes gasoline costs
Nakheel awards $144m Dubai Islands infrastructure contract
AI surges as focus for strategic planning
NATO'S RUTTE TO MEET ERDOGAN IN ANKARA APR. 21-22...
CaixaBank Plans 60% Workforce Expansion in London
AST SpaceMobile Shares Decline Following Satellite Deployment Error
Canada's March Inflation Rate Rises to 2.4% Amid Energy Price Surge
AST SpaceMobile Stock Declines Following Satellite Loss in Blue Origin Launch
Accenture Collaborates with Avanade and Microsoft on AI Factory Intelligence System
PayPay Corporation Debuts on Nasdaq, Marking Key Development for Japanese Tech Sector
Study Highlights Predictive Value of Ignite Proteomics' RPPA Platform for Breast Cancer Therapy
GE Vernova Faces Legal Challenges Amid Growing Energy Sector Demand
Worthington Steel Achieves Top Supplier Rating from John Deere for 14th Year
Gogo Faces Diverging Analyst Opinions Amid Guidance Changes
Morgan Stanley Increases Intel Price Target Amid Stronger Server Demand
SLB Adjusts Fair Value Estimate Amid Analyst Target Revisions
Late April Declared Optimal Time for Home Listings in the U.S.
Novo Nordisk Launches DKK 15 Billion Share Repurchase Programme
Debate Emerges Over SpaceX IPO Valuation
U.S. Government to Refund $166 Billion in Tariffs Following Supreme Court Ruling
Iran War Inflation Likely To Stick Even After Ceasefire, Economists Say
Canadian Strategic Missions Corporation to lead $3 million government-backed project to advance manufacturing for nuclear micro-reactors
Canada Inflation Jumps to 2.4% as Iran War Drives Up Gas Prices
Ed Miliband unveils move to delink gas and electricity prices
Accenture's New Agentic Factory System Debuts With Microsoft
Bristow Group Announces Planned Retirement of Chief Operating Officer, Government Services
CD&R-backed Multi-Color secures court approval for $4bn debt overhaul
AUSTRIA ECONOMY MINISTRY: OMV TAPS 56,000 TONS CRUDE FROM AUSTRIAN EMERGENCY RESERVES...
Morgan Stanley Recommends Apple as Tactical Long Ahead of Earnings
S&P 500 Investors Shift Focus to Growth Amid Easing Oil Supply Concerns
Alphabet Inc. Ranks High Among AI Stock Picks
Stocks Show Strong Momentum Ahead of Broader Market
Homebuyers Gain Negotiating Power in 38 Major U.S. Metros
Fermi (FRMI) Stock Plunges 20% as Top Executives Resign Amid Major Restructuring
Iran Hesitant on Talks as Tensions Rise After US Seizes Ship
QALIBAF HAS ALSO EXPRESSED CONCERN REGARDING HIS REMOVAL FROM THE PRESIDENCY OF THE PARLIAMENT AND...
Chevron, Exxon Mobil rise premarket; AST SpaceMobile slumps
German union renews calls for Commerzbank independence after UniCredit’s latest push
Bond investors propose crisis ’pause clauses’ for emerging countries
FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX for Bladder Cancer Treatment
Merck has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) concerning its anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The applications also include KEYTRUDA QLEX™, which combines pembrolizumab with berahyaluronidase alfa-pmph. Both treatments are being evaluated in conjunction with Padcev® (enfortumab vedotin-ejfv) for patients diagnosed with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
The priority review designation is intended to expedite the regulatory process for therapies that may offer significant improvements in treatment options for serious conditions. This review will assess the efficacy and safety of the combinations in the specified patient population, potentially leading to quicker access for those in need of new treatment alternatives. Merck continues to advance its commitment to addressing unmet medical needs in oncology.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News